Development of a treatment and preventive drug for MRONJ Using E. coli derived rhBMP-2

2023 Fiscal Year Final Research Report

• Project/Area Number: 22K17112
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 57050:Prosthodontics-related
• Research Institution: Okayama University
• Principal Investigator: mikai akihiro 岡山大学, 歯学部, 客員研究員 (20845375)
• Project Period (FY): 2022-04-01 – 2024-03-31
• Keywords: MRONJ / BMP-2

Outline of Final Research Achievements

Medication-related osteonecrosis of the jaw (MRONJ) has unknown aspects regarding its onset and pathology. This study examined the effects of MRONJ and BMP-2 (Bone Morphogenetic Protein-2) treatment on the microstructure, osteocyte networks and bone remodeling around the extraction socket. In the MRONJ model, bone matrix cracking, reduced osteocyte networks, and delayed bone remodeling were observed. BMP-2-containing artificial bone transplantation restored these conditions to levels comparable to healthy bone.

Free Research Field

バイオロジー

Academic Significance and Societal Importance of the Research Achievements

高齢化が進む日本では骨粗鬆症患者が増加し，治療にビスフォスフォネート（BP）製剤が使用されている．しかし，BP製剤は強力な骨吸収抑制作用を持つ一方で，侵襲的歯科治療により顎骨壊死が発生することが社会問題となっている．顎骨壊死の発症メカニズムや病態を正確に理解し，新たな治療法を開発することは，患者のQOL（生活の質）を向上させるだけでなく，医療費の削減にも寄与するため，社会的に重要である．